Bristol Myers Squibb Maintains Positive Outlook for 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 22 hours ago
0mins
Source: Fool
- Earnings Highlights: Bristol Myers Squibb reported a 1% year-over-year revenue increase in Q4 2025, reaching $12.5 billion, despite a nearly 24% drop in non-GAAP net income to $2.6 billion, demonstrating resilience amid drug price cuts.
- Growth Portfolio Performance: The growth portfolio, led by the cancer drug Opdivo, saw a 16% revenue increase to nearly $7.4 billion, contrasting with a 15% decline in the legacy portfolio's revenue to $5.1 billion, indicating strong potential in new drug development.
- Positive Guidance: Management forecasts total revenue between $46 billion and $47.5 billion for 2026, with adjusted net income of $6.05 to $6.35 per share, both exceeding analyst expectations, reflecting confidence in future performance.
- FDA Approval Progress: The FDA accepted Bristol Myers Squibb's new drug application for iberdomide and reported positive Phase 2 trial results for Reblozyl, enhancing the company's competitive edge in multiple myeloma treatment and signaling future growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 60.290
Low
37.00
Averages
55.86
High
68.00
Current: 60.290
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bristol Myers Squibb Reports Positive Phase 3 Trial Results
- Successful Clinical Trial: Bristol Myers Squibb's SUCCESSOR-2 study shows that oral mezigdomide combined with carfilzomib and dexamethasone significantly improves progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma, indicating the combination therapy's clinical significance.
- Safety Consistency: The safety findings align with the known profile of mezigdomide, suggesting good safety in combination therapy, with patients continuing to be monitored for survival and safety to ensure long-term efficacy.
- Study Design Features: The SUCCESSOR-2 study is a multicenter, randomized, open-label Phase 2/3 trial primarily assessing the efficacy and safety of mezigdomide, with PFS as the primary endpoint, providing crucial evidence for future clinical applications.
- Key Secondary Endpoints: The study also focuses on several key secondary endpoints, including overall survival (OS) and overall response rate (ORR), which will further evaluate the comprehensive efficacy of the treatment regimen and its impact on patient quality of life, holding significant clinical value.
See More
Bristol Myers Squibb's Cancer Drug Meets Key Trial Goals
- Clinical Trial Success: Bristol Myers Squibb's experimental cancer drug mezigdomide achieved its primary goal in a late-stage study for relapsed or refractory multiple myeloma, demonstrating statistically significant and clinically meaningful improvement in progression-free survival compared to carfilzomib and dexamethasone alone.
- Combination Therapy Advantage: The combination of mezigdomide with carfilzomib and dexamethasone in the SUCCESSOR-2 trial shows potential in treating rare blood cancers, indicating a new treatment option for patients.
- Safety Consistency: The safety findings were consistent with the known profile of mezigdomide, suggesting its acceptability in clinical use and enhancing confidence in its market introduction.
- Strategic Implications: This successful Phase 3 trial marks the first positive outcome for mezigdomide and the second positive Phase 3 study for Bristol Myers Squibb's CELMoD program, further solidifying the company's core strength in oncology.
See More
Bristol Myers Squibb Highlights from 2025 Earnings Report
- Revenue Growth: Bristol Myers Squibb's Q4 2025 revenue increased by 1% year-over-year to $12.5 billion, despite a nearly 24% drop in net income to $2.6 billion, indicating a balance between growth and decline.
- New Drug Application Progress: The FDA has accepted Bristol Myers Squibb's new drug application for iberdomide for multiple myeloma, marking a significant advancement in the company's innovative drug development that could provide new revenue streams in the future.
- Growth Portfolio Performance: While the legacy portfolio's revenue fell by 15% to $5.1 billion, the growth portfolio, particularly the cancer drug Opdivo, saw a 16% increase to $7.4 billion, showcasing the company's strong performance in new drug areas.
- Optimistic Future Outlook: Management expects 2026 revenue to range between $46 billion and $47.5 billion, with adjusted net income of $6.05 to $6.35 per share, both exceeding analyst expectations, reflecting the company's confidence in future growth.
See More
Bristol Myers Squibb Maintains Positive Outlook for 2026
- Earnings Highlights: Bristol Myers Squibb reported a 1% year-over-year revenue increase in Q4 2025, reaching $12.5 billion, despite a nearly 24% drop in non-GAAP net income to $2.6 billion, demonstrating resilience amid drug price cuts.
- Growth Portfolio Performance: The growth portfolio, led by the cancer drug Opdivo, saw a 16% revenue increase to nearly $7.4 billion, contrasting with a 15% decline in the legacy portfolio's revenue to $5.1 billion, indicating strong potential in new drug development.
- Positive Guidance: Management forecasts total revenue between $46 billion and $47.5 billion for 2026, with adjusted net income of $6.05 to $6.35 per share, both exceeding analyst expectations, reflecting confidence in future performance.
- FDA Approval Progress: The FDA accepted Bristol Myers Squibb's new drug application for iberdomide and reported positive Phase 2 trial results for Reblozyl, enhancing the company's competitive edge in multiple myeloma treatment and signaling future growth potential.
See More
Bristol Myers Squibb Receives FDA Approval for New Drug
- FDA Approval: Bristol Myers Squibb's Sotyktu (deucravacitinib) has received FDA approval for the treatment of active psoriatic arthritis (PsA), marking the first selective tyrosine kinase 2 (TYK2) inhibitor approved for this condition, representing a significant advancement in treatment options.
- Clinical Trial Results: The FDA's decision was based on positive outcomes from the pivotal POETYK PsA-1 and POETYK PsA-2 trials, which demonstrated that a daily dose of 6 mg of Sotyktu significantly improved disease activity, primarily measured by the American College of Rheumatology 20 (ACR20) response.
- Drug History: Initially approved in 2022 for moderate-to-severe plaque psoriasis, Sotyktu is not recommended for use with other potent immunosuppressants, highlighting its unique safety profile and therapeutic potential in the treatment landscape.
- Market Reaction: Although BMY's stock closed down 0.74% at $60.29 on March 6 and slipped further to $60.01 in after-hours trading, the FDA approval may open new market opportunities and growth potential for the company.
See More
Bristol Myers Squibb's Sotyktu Approved for Psoriatic Arthritis Treatment
- New Drug Approval: Bristol Myers Squibb's oral drug Sotyktu has received FDA approval for treating adults with active psoriatic arthritis, providing a new treatment option for alleviating joint and skin symptoms.
- Clinical Trial Results: In two global Phase 3 studies, 54% of patients taking Sotyktu achieved an ACR20 response by Week 16, compared to only 34% and 39% in the placebo groups, demonstrating significant treatment efficacy.
- Safety Profile: The drug's safety profile is similar to earlier psoriasis studies, with common side effects including respiratory infections and mouth ulcers; the FDA mandates tuberculosis screening before treatment to mitigate infection risks.
- Market Impact: This approval underscores Sotyktu's critical role in managing psoriatic arthritis, potentially enhancing Bristol Myers Squibb's position in the immunology market and driving further development in immune-related diseases.
See More
Bristol Myers Squibb Reports Positive Phase 3 Trial Results
- Successful Clinical Trial: Bristol Myers Squibb's SUCCESSOR-2 study shows that oral mezigdomide combined with carfilzomib and dexamethasone significantly improves progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma, indicating the combination therapy's clinical significance.
- Safety Consistency: The safety findings align with the known profile of mezigdomide, suggesting good safety in combination therapy, with patients continuing to be monitored for survival and safety to ensure long-term efficacy.
- Study Design Features: The SUCCESSOR-2 study is a multicenter, randomized, open-label Phase 2/3 trial primarily assessing the efficacy and safety of mezigdomide, with PFS as the primary endpoint, providing crucial evidence for future clinical applications.
- Key Secondary Endpoints: The study also focuses on several key secondary endpoints, including overall survival (OS) and overall response rate (ORR), which will further evaluate the comprehensive efficacy of the treatment regimen and its impact on patient quality of life, holding significant clinical value.
See More
Bristol Myers Squibb's Cancer Drug Meets Key Trial Goals
- Clinical Trial Success: Bristol Myers Squibb's experimental cancer drug mezigdomide achieved its primary goal in a late-stage study for relapsed or refractory multiple myeloma, demonstrating statistically significant and clinically meaningful improvement in progression-free survival compared to carfilzomib and dexamethasone alone.
- Combination Therapy Advantage: The combination of mezigdomide with carfilzomib and dexamethasone in the SUCCESSOR-2 trial shows potential in treating rare blood cancers, indicating a new treatment option for patients.
- Safety Consistency: The safety findings were consistent with the known profile of mezigdomide, suggesting its acceptability in clinical use and enhancing confidence in its market introduction.
- Strategic Implications: This successful Phase 3 trial marks the first positive outcome for mezigdomide and the second positive Phase 3 study for Bristol Myers Squibb's CELMoD program, further solidifying the company's core strength in oncology.
See More
Bristol Myers Squibb Highlights from 2025 Earnings Report
- Revenue Growth: Bristol Myers Squibb's Q4 2025 revenue increased by 1% year-over-year to $12.5 billion, despite a nearly 24% drop in net income to $2.6 billion, indicating a balance between growth and decline.
- New Drug Application Progress: The FDA has accepted Bristol Myers Squibb's new drug application for iberdomide for multiple myeloma, marking a significant advancement in the company's innovative drug development that could provide new revenue streams in the future.
- Growth Portfolio Performance: While the legacy portfolio's revenue fell by 15% to $5.1 billion, the growth portfolio, particularly the cancer drug Opdivo, saw a 16% increase to $7.4 billion, showcasing the company's strong performance in new drug areas.
- Optimistic Future Outlook: Management expects 2026 revenue to range between $46 billion and $47.5 billion, with adjusted net income of $6.05 to $6.35 per share, both exceeding analyst expectations, reflecting the company's confidence in future growth.
See More
Bristol Myers Squibb Maintains Positive Outlook for 2026
- Earnings Highlights: Bristol Myers Squibb reported a 1% year-over-year revenue increase in Q4 2025, reaching $12.5 billion, despite a nearly 24% drop in non-GAAP net income to $2.6 billion, demonstrating resilience amid drug price cuts.
- Growth Portfolio Performance: The growth portfolio, led by the cancer drug Opdivo, saw a 16% revenue increase to nearly $7.4 billion, contrasting with a 15% decline in the legacy portfolio's revenue to $5.1 billion, indicating strong potential in new drug development.
- Positive Guidance: Management forecasts total revenue between $46 billion and $47.5 billion for 2026, with adjusted net income of $6.05 to $6.35 per share, both exceeding analyst expectations, reflecting confidence in future performance.
- FDA Approval Progress: The FDA accepted Bristol Myers Squibb's new drug application for iberdomide and reported positive Phase 2 trial results for Reblozyl, enhancing the company's competitive edge in multiple myeloma treatment and signaling future growth potential.
See More
Bristol Myers Squibb Receives FDA Approval for New Drug
- FDA Approval: Bristol Myers Squibb's Sotyktu (deucravacitinib) has received FDA approval for the treatment of active psoriatic arthritis (PsA), marking the first selective tyrosine kinase 2 (TYK2) inhibitor approved for this condition, representing a significant advancement in treatment options.
- Clinical Trial Results: The FDA's decision was based on positive outcomes from the pivotal POETYK PsA-1 and POETYK PsA-2 trials, which demonstrated that a daily dose of 6 mg of Sotyktu significantly improved disease activity, primarily measured by the American College of Rheumatology 20 (ACR20) response.
- Drug History: Initially approved in 2022 for moderate-to-severe plaque psoriasis, Sotyktu is not recommended for use with other potent immunosuppressants, highlighting its unique safety profile and therapeutic potential in the treatment landscape.
- Market Reaction: Although BMY's stock closed down 0.74% at $60.29 on March 6 and slipped further to $60.01 in after-hours trading, the FDA approval may open new market opportunities and growth potential for the company.
See More
Bristol Myers Squibb's Sotyktu Approved for Psoriatic Arthritis Treatment
- New Drug Approval: Bristol Myers Squibb's oral drug Sotyktu has received FDA approval for treating adults with active psoriatic arthritis, providing a new treatment option for alleviating joint and skin symptoms.
- Clinical Trial Results: In two global Phase 3 studies, 54% of patients taking Sotyktu achieved an ACR20 response by Week 16, compared to only 34% and 39% in the placebo groups, demonstrating significant treatment efficacy.
- Safety Profile: The drug's safety profile is similar to earlier psoriasis studies, with common side effects including respiratory infections and mouth ulcers; the FDA mandates tuberculosis screening before treatment to mitigate infection risks.
- Market Impact: This approval underscores Sotyktu's critical role in managing psoriatic arthritis, potentially enhancing Bristol Myers Squibb's position in the immunology market and driving further development in immune-related diseases.
See More
